Using this approach we have identified the nuclear hormone receptor PPARG, the metalloproteinase ADAMTS5, and the aldo-keto reductase AKR1B10 as potential drug targets for treatment of osteoporosis and obesity. Here, AKR1B10 is linked to obesity due to melanocortin 4 receptor deficiency.